A new UK-based pharmaceutical company, Cambrio, has been launched in London, with the publishing of its pathfinder prospectus ahead of a listing on the London Stock Exchange next month.
The firm is the brainchild of Nowell Stebbing, who steered another UK biotechnology company, Chiroscience, through a flotation in 1994, raising L45 million ($69 million; Marketletters passim).
Cambrio says it provides skilled technical services to the international drug industry, manufactures and distributes specialist products to niche markets, develops and manufactures branded medicinal products, and is researching and developing a new generation of medicinal products from plant extracts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze